Cell based cancer vaccines
DCprime has both the infrastructure and capabilities to bring cancer immunotherapeutics to clinic. Initially exploiting the proprietary DCOne® platform, DCprime is developing cell based vaccines against different types of cancer.
Read more
Immuno-oncology beyond T cells
Since successful vaccination requires an immune system capable of mounting an effective response to the vaccine, DCprime continues to invest in research into furthering understanding of the condition of the immune system during or after treatment of cancer.
Read more

 

 

News

  • Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer 12 October, 2018     Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer Leiden, The Netherlands, October 01, 2018 – DCprime announces today that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect. Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 15 years ... Read more
  • Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy 26 July, 2018     Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy. Leiden, The Netherlands, 26 July 2018 – DCprime announces that the results of the phase I study with its lead product DCP-001 in AML have been published in Cancer Immunology, Immunotherapy. The phase I study was ... Read more
  • DCprime and Glycotope announce licensing agreement and collaboration 18 July, 2018     DCprime and Glycotope announce licensing agreement and collaboration Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime bv, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have entered into a license agreement and research collaboration. Under ... Read more